All In Biotech

Drug Trial Radar · NCT04670679

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Dec 15, 2020

Primary completion

Feb 1, 2026

Study completion Jun 1, 2026

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • ERAS-601Drug

    Administered orally

  • CetuximabDrug

    Administered via intravenous infusion

  • PembrolizumabDrug

    Administered via intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
  2. Maximum tolerated dose (MTD)Time frame: Study Day 1 up to Day 29
  3. Recommended dose (RD)Time frame: Study Day 1 up to Day 29
  4. Adverse EventsTime frame: Assessed up to 24 months from time of first dose
  5. Plasma concentration (Cmax)Time frame: Study Day 1 up to Day 29
  6. Time to achieve Cmax (Tmax)Time frame: Study Day 1 up to Day 29
  7. Area under the curveTime frame: Study Day 1 up to Day 29
  8. Half-lifeTime frame: Study Day 1 up to Day 29

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Sarah Cannon Research Institute (Florida Cancer Specialists)

    Sarasota, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute (Tennessee Oncology)

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.